Additional Proxy Soliciting Materials (definitive) (defa14a)
May 21 2021 - 4:11PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
14A
(Rule
14a-101)
INFORMATION
REQUIRED IN PROXY STATEMENT
SCHEDULE
14A INFORMATION
Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed
by the Registrant ☒
Filed
by a Party other than the Registrant ☐
Check
the appropriate box:
☐
|
Preliminary
Proxy Statement
|
☐
|
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☐
|
Definitive
Proxy Statement
|
☒
|
Definitive
Additional Materials
|
☐
|
Soliciting
Material Pursuant to §240.14a-12
|
OncoCyte
Corporation
(Name
of Registrant as Specified in Its Charter)
(Name
of Person(s) Filing Proxy Statement if other than the Registrant)
Payment
of Filing Fee (Check the appropriate box):
|
☒
|
No
fee required.
|
☐
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1)
|
Title
of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate
number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
the filing fee is calculated and state how it was determined):
|
|
|
|
|
(4)
|
Proposed
maximum aggregate value of transaction:
|
|
|
|
|
(5)
|
Total
fee paid:
|
|
|
|
☐
|
Fee
paid previously with preliminary materials.
|
☐
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date
of its filing.
|
|
(1)
|
Amount
previously paid:
|
|
|
|
|
(2)
|
Form,
schedule or registration statement no.:
|
|
|
|
|
(3)
|
Filing
party:
|
|
|
|
|
(4)
|
Date
filed:
|
|
|
|
|
15
Cushing Road
|
Irvine,
CA 92618
|
|
+844.ONCOCYTE
|
+844.662.6298
|
+949.409.7600
|
|
customer.service@oncocyte.com
|
oncocyte.com
|
May
21, 2021
Dear
Oncocyte Shareholder,
To
say 2020 was a fascinating year would be quite an understatement! As I write, the United States is in full vaccination mode from
the worst pandemic in over a century and our way of life is slowly returning to what will certainly be a “New Normal”.
Despite the macroenvironmental challenges of the past year, Oncocyte stayed true to our mission and has entered 2021 much stronger
than we entered 2020!
2020
was a transformational year for our company with numerous milestones achieved:
|
●
|
DetermaRx
was launched in the spring as the pandemic started, and despite the incredible headwind we encountered, we were able to onboard
82 hospitals,138 treating physicians and identified over 100 patients who were high risk for recurring Non-Small Cell Lung
Cancer.
|
|
|
|
|
●
|
We
acquired Insight Genetics in late January of 2020, and within 90 days we validated and launched DetermaIO™ into the
pharma clinical trial market as the only precision diagnostic available that can predict which patients will have a sustained
response to immune therapy. In the past six months, our increased investments in clinical studies have yielded numerous papers
and abstracts that have now validated DetermaIO in Non-Small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
and Bladder Cancer, with more on the way. We remain excited about the continued success of DetermaIO and look forward to launching
the test to the clinical market in the second half of 2021
|
|
|
|
|
●
|
In
the Fall of 2020, we evaluated Chronix Biomedical’s IP and technology, including TheraSure™ CNI, as a way to enter
the emerging $15B blood-based monitoring market for therapeutic response and recurrence monitoring. Our diligence led to our
acquisition of Chronix in April. We expect Chronix’ CNI technology and IP will be the foundation of our entry into this
exciting and very large market opportunity. We believe TheraSure™ CNI, which we plan to re-brand as DetermaCNI™,
will have clinical use in monitoring a patient’s response to cancer treatment, including but not limited to immunotherapy
treatment.
|
|
|
|
|
●
|
Last
April, following our acquisition of Insight Genetics, we launched our Pharma Services from our newly acquired CLIA and CAP
certified lab in Nashville Tennessee, giving us an east coast presence from which we are delivering a robust offering of molecular
laboratory services to pharma companies and diagnostic platform providers.
|
I
am extremely proud of our small but dedicated team and feel incredibly fortunate to lead such an outstanding group of professionals!
They weathered the challenges of working through incredibly difficult circumstances over the past year, and have met every milestone
we set for ourselves, on time. In only 6 quarters, we have transitioned Oncocyte from a company with a single product focus to
an emerging leader in the world of oncology diagnostics with a solid menu of novel tests. We have now accumulated the technologies
we need to execute on our vision of becoming the first choice of physicians helping their patients make the major treatment decisions
confronting cancer patients each day.
We
appreciate the relentless support of our shareholders and stakeholders! Without you we would not be in such a strong position
to fulfill our mission and deliver significant shareholder value over the coming years. The future is incredibly bright, and we
look forward to sharing it with you.
Together
in the fight!
Ron
A. Andrews
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoCyte (AMEX:OCX)
Historical Stock Chart
From Sep 2023 to Sep 2024